TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Phase IIb Safety and Efficacy Study of DE-126 Ophthalmic Solution in Primary Open-Angle Glaucoma or Ocular Hypertension- Angel Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Provide signed written informed consent~* Diagnosis of POAG or OHT in both eyes~* Qualifying corrected visual acuity in each eye~* Qualifying central corneal thickness in each eye~* Qualifying Day 1 IOP measurement at 3 time-points in both eyes~* Qualifying Anterior chamber angle~Exclusion Criteria:~* History of ocular surgery specifically intended to lower IOP~* Subjects who cannot safely discontinue use of ocular hypotensive medications during the wait/washout period~* Advanced glaucoma in either eye~* Any corneal abnormality or other condition interfering with or preventing reliable Goldmann applanation tonometry~* Any ocular surgery or ocular laser treatment within 90 days prior to Visit 1 (Screening) and throughout the study in either eye~* Females who are pregnant, nursing, or planning a pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Vehicle of DE-126) followed by high dose of DE-126 (Type: PLACEBO_COMPARATOR): None
- Ultra-low dose 0.0005% DE-126 (Type: EXPERIMENTAL): None
- Low dose 0.001% DE-126 (Type: EXPERIMENTAL): None
- Medium dose 0.002% DE-126 (Type: EXPERIMENTAL): None
- High dose 0.003% DE-126 (Type: EXPERIMENTAL): None
- 0.005% Latanoprost (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of AJU-A51 in Type 2 Diabetes Mellitus Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Those who voluntarily signed the informed consent to participate in this study.~* Adults aged 19-75 years.~* Those diagnosed with type 2 diabetes mellitus.~* 7% ≤ HbA1c ≤ 10.5%~* FPG ≤ 270 mg/dL~* BMI ≤ 40 kg/㎡~* Subjects able to understand the study, comply with study procedures, and attend all scheduled visits.~Exclusion Criteria:~* Those who suffered from acute or chronic metabolic acidosis, lactic acidosis and diabetic ketoacidosis.~* Those who had genetic disorders such as galactose intolerance, Lapp lactose deficiency, or glucose-galactose malabsorption.~* Those with heart failure (NYHA class II\~IV) or who had suffered from heart failure.~* Those with a history of malignant tumor within 5 years~* Those who have a clinically significant liver disease~* Those who have a clinically significant renal disease~* SBP \> 180 mmHg or DBP \> 110 mmHg~* Those who had allergic reaction to main ingredients or components of the investigational products.~* Patients planning to become pregnant or of childbearing potential, but not using any recognized contraceptive method~* Females who are pregnant or breastfeeding.~* AST or ALT ≥ LRN\*3~* TG ≥ 500 mg/dL

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- AJU-A51+A51R2 placebo+A51R3 (Type: EXPERIMENTAL): None
- AJU-A51 placebo+A51R2+A51R3 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Advanced Renal Cell Carcinoma~* Must have at least 1 lesion with measurable disease~* Life expectancy of at least 3 months~* Karnofsky Performance Status (KPS) must be =\>70%~Exclusion Criteria:~* Patients/subjects with suspected or known central nervous system metastases unless adequately treated~* Patients/subjects with autoimmune disease~* Patients/subjects who need daily oxygen therapy~Other protocol defined inclusion/exclusion criteria apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nivolumab + Ipilimumab (Type: ACTIVE_COMPARATOR): Nivolumab + Ipilimumab
- Nivolumab + Relatlimab (Type: EXPERIMENTAL): Nivolumab + Relatlimab
- Nivolumab + BMS-986205 (Type: EXPERIMENTAL): Nivolumab + BMS-986205
- Nivolumab + BMS-813160 (Type: EXPERIMENTAL): Nivolumab + BMS-813160 (CCR2/5 dual antagonist)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intra-pocket Application of Tea Tree Oil Gel in the Treatment of Stage-2 Periodontitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients diagnosed with stage 2,grade B periodontitis according to the 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions.~* Patients with CAL 3-4 mm , BOP and radiographic horizontal bone loss related to the coronal third of the root (15%-33%).~* Patients with no teeth loss due to periodontitis.~* Patients with radiographic bone loss/age % of 0.25-1 %.~* Patients who could maintain an O'Leary plaque index ≤10 proceeded into the study.~Exclusion Criteria:~* Patients with CAL caused by non periodontal causes.~* Patients with grade C periodontitis.~* Patients having any systemic disease that may affect the treatment outcomes~* Smokers.~* Pregnant females.~* Patients receiving contraindicated medications, chemotherapy, or radiotherapy in the previous year.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Scaling and Root Planing (SRP) (Type: ACTIVE_COMPARATOR): None
- Scaling and Root Planing with tea tree oil (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Measurements of Kidney Perfusion After Transplantation by Intraoperative Fluorescence Angiography

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients receiving kidney transplantation~* Deceased donor and living donor transplantations~Exclusion Criteria:~* Allergy against indocyanine green~* Iodine allergy~* Contrast allergy~* Penicillin allergy~* Allergic diathesis~* Liver insufficiency~* Pregnancy~* Hyperthyreosis~* Pulmonary arterial hypertension

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- kidney transplantation (Type: EXPERIMENTAL): Intravenous injection of Indocyanine Green in patients receiving kidney transplantation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis (VANISH 303)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Subject is a postmenarchal female subject 12 years and older~Subject has a diagnosis of symptomatic AVVC at baseline including a positive microscopic examination with 10% KOH in a vaginal sample revealing yeast forms (hyphae/pseudohyphae) or budding yeasts, and vaginal pH (≤4.5)~Exclusion Criteria:~Subject has any vaginal condition other than AVVC that may interfere with the diagnosis or evaluation of response to therapy, such as suspected or confirmed concurrent causes of vulvovaginitis and/or cervicitis (mixed infection)~Need for systemic and/or topical (vaginal) antifungal treatment, including prescription or over-the-counter products during the study and treatment for VVC 28 days prior to randomization~Subject is actively menstruating at the time of the Baseline visit.~Subject has uncontrolled diabetes mellitus.~Subject has a vaginal sample with pH \>4.5.~Subject has a history of or an active cervical/vaginal cancer.

- Gender: FEMALE
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ibrexafungerp (SCY-078) (Type: EXPERIMENTAL): 300 mg orally every 12 hrs for 1 day (2 doses in 1 day)
- Placebo (Type: PLACEBO_COMPARATOR): Matching Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Subcuticular Suture for Cesarean Skin Incision Closure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Gestational age of 37 completed weeks or greater based on their estimated due date calculated from last menstrual period or early ultrasound.~* Patients participating will be undergoing either:~  * Scheduled cesarean delivery~ * Non-emergent cesarean delivery~Exclusion Criteria:~* Urogenital tract infection within 2 weeks prior to surgery~* Chronic oral or injectable steroid use (\> 2 weeks)~* Emergency cesarean delivery (need to deliver immediately due to a maternal or fetal indication)~* Vertical skin incision~* Active participation in another research study

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- poliglecaprone 25 suture (Type: EXPERIMENTAL): Subcuticular skin approximation with poliglecaprone 25 suture at cesarean birth surgery
- polyglactin 910 suture (Type: EXPERIMENTAL): Subcuticular skin approximation with polyglactin 910 suture at cesarean birth surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Knee Osteoarthritis With Allogenic Mesenchymal Stem Cells

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Knee osteoarthritis grade II, III and IV of Kellgren and Lawrence assessed by two observers.~* Chronic knee pain with mechanical characteristics.~* No local or systemic septic process.~* Haematological and biochemical analysis without significant alterations that contraindicate treatment.~* Informed written consent of the patient.~* The patient is able to understand the nature of the study~Exclusion Criteria:~* Age over 75 or under 18 years or legally dependent~* Present Infection (to be included in the study no signs of infection must be evidenced)~* Congenital or acquired malformation resulting in significant deformity of the knee (varus\<10º; valgus\<20º) and leading to problems in application or evaluation of results.~* Overweight expressed as body mass index (BMI) greater than 30.5 (obesity grade II). BMI estimated as mass (kg) / corporal surface (m2).~* Women who are pregnant or intend to become pregnant or breast-feeding~* Neoplasia~* Immunosuppressive states~* Intra-articular infiltartion of any treatments in the last 3 months previous to study inclusion~* Participation in another clinical trial or treatment with a different investigational product within 30 days prior to inclusion in the study.~* Other pathologic conditions or circumstances that difficult participation in the study according to medical criteria

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Allogenic mesenchymal stromal cells injection (Type: EXPERIMENTAL): Mesenchymal stem cells (MSC) prepared from bone marrow from healthy donor expanded ex vivo for 3-4 weeks. Intraarticular injection of 40 millions MSC.
- Hyaluronic acid (Durolane) (Type: ACTIVE_COMPARATOR): Intraarticular injection of hyaluronic acid (60 mg)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Musculoskeletal Plasticity After Spinal Cord Injury

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Motor complete SCI (AIS A-B)~Exclusion Criteria:~1. Pressure ulcers~2. Chronic infection~3. Lower extremity muscle contractures~4. Deep vein thrombosis~5. Bleeding disorder~6. Recent limb fractures~7. Any comorbid disease known to affect bone metabolism (such as parathyroid dysfunction)~8. Pregnancy~9. Anti-osteoporosis medications~10. Vitamin D supplements~11. Metformin or other medications for diabetes.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Acute gene regulation (Type: EXPERIMENTAL): Adaptations in gene regulation in response to single-session electrically induced exercise
- Training Study (Type: EXPERIMENTAL): Adaptations in gene regulation, metabolic markers, and subject-report metrics in response to up to 3 years of electrically induced exercise

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Esketamine Combined With Pregabalin on Acute Postoperative Pain in Patients Undergoing Resection of Spinal Neoplasms.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient undergoing elective spinal cord neoplasms resection;~* Ages between 18 and 65 years old;~* American Society of Anaesthesiology (ASA) status I-III;~* Signed informed consent.~Exclusion Criteria:~* Previous adverse reaction to ketamine, s-ketamine or pregabalin;~* Patients with a diagnosed history of severe chronic pain;~* Patients with long-term analgesic treatment(gabapentin/opioids/ketamine);~* Patients with aphasia or inability to cooperate with the pain assessments;~* Known sever insufficiency of vitals(such as heart failure/renal dysfunction/hepatic failure);~* Patients with a diagnosed history of psychiatric disorder;~* Patients treated with gabapentin/pregabalin in the last three months;~* Drug abuse;~* Body mass index (BMI) \> 35 kg/m2 ;~* Pregnancy or lactation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- S-ketamine and pregabalin (Type: EXPERIMENTAL): None
- Normal saline and placebo capsule (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Confirmatory Study of OPC-12759 Ophthalmic Solution

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Out patient~2. Subjective complaint of dry eye that has been present for minimum 20 months~3. Ocular discomfort severity is moderate to severe~4. Corneal - conjunctival damage is moderate to severe~5. Unanesthetized Schirmer's test score of 5mm/5minutes or less~6. Best corrected visual acuity of 0.2 or better in both eyes~Exclusion Criteria:~1. Presence of anterior segment disease or disorder other than that associated with dry eye~2. Ocular hypertension patient or glaucoma patient with ophthalmic solution~3. Anticipated use of any topically-instilled ocular medications or patients who cannot discontinue the use during the study~4. Anticipated use of contact lens during the study~5. Patient with punctal plug~6. Any history of ocular surgery within 12 months~7. Female patients who are pregnant,possibly pregnant or breast feeding~8. Known hypersensitivity to any component of the study drug or procedural medications~9. Receipt of any investigational product within 4 months.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- OPC-12759 ophthalmic solution (Type: EXPERIMENTAL): OPC-12759 ophthalmic solution
- Placebo (Type: PLACEBO_COMPARATOR): OPC-12759 ophthalmic solution 0%
- OPC-12759 ophthalmic suspension (Type: ACTIVE_COMPARATOR): OPC-12759 ophthalmic suspension

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Losartan in Patients With Nonobstructive Hypertrophic Cardiomyopathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with hypertrophic cardiomyopathy~* Left ventricular outflow tract (LVOT) gradient less than 30 mm Hg at rest~* Age 18 years or older~Exclusion Criteria:~* Contraindication to losartan~* Already taking losartan~* Contraindication to MRI~* Hemodynamic instability

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- losartan (Type: EXPERIMENTAL): Losartan 50 mg b.i.d.
- placebo (Type: PLACEBO_COMPARATOR): Placebo b.i.d.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Prospective Observational Registry of Peripheral Use of AngioJet Rheolytic Thrombectomy With Mid-Length Catheters

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patient has been treated with a mid-length AngioJet catheter(defined as 90-120 cm in length)~* Patient has provided appropriate authorization per institutional policy and procedure.~Exclusion Criteria:~* None

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Limb Ischemia (Type: None): Patients presenting with limb ischemia for treatment
- Deep Vein Thrombosis (Type: None): Patients presenting with deep vein thrombosis for treatment
- Hemodialysis Access (Type: None): Patients presenting with thrombosed hemodialysis access for treatment
- Other Thrombotic Conditions (Type: None): Patients presenting with thrombosed conditions other than limb ischemia, deep vein thrombosis or thrombosed hemodialysis access for treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of MK-217A/Alendronate Sodium 70-mg/Vitamin D3 5600 IU Combination Tablet (MK-0217A-329)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Man aged 50 or older, or a woman who is postmenopausal on day of signing informed consent or has been menopausal for at least one year~* Meets bone mineral density (BMD) criteria~* Agree to discontinue any osteoporosis drug treatment for duration of study~Exclusion Criteria:~* Any contraindication to alendronate and vitamin D~* Not ambulatory~* Has received treatment with any anabolic steroid agent within the past 12 months, systemic glucocorticoids, for more than 2 weeks in the past 6 months, current use of immunosuppressants, fluoride treatment at a dose greater than 1 mg/day for more than 2 weeks within the past 3 months, treated with parathyroid hormone (PTH) for more than 2 weeks within the past 3 months, current use of chemotherapy or heparin, use of growth hormone for more than 2 weeks within the past 6 months, use of active hormonal vitamin D analogs in the past 2 months, current use of vitamin A \>10,000 IU daily, current use of, lithium, or anti-convulsants including barbiturates, hydantoins, and carbamazepine, current use of calcium supplement in amount excess of 1500 mg daily, and/or current use of Vitamin D supplement~* History of malignancy \<5 years, except adequately treated basal cell or squamous cell skin cancer and in situ cervical cancer~* One or more of the following concomitant conditions: Upper gastrointestinal (GI) disorders not adequately controlled; myocardial infarction, unstable angina, stroke and revascularization condition within 3 months; malabsorption syndrome; primary or secondary hyperparathyroidism not adequately treated; thyroid disease not adequately controlled; severe renal insufficiency; uncontrolled genitourinary, cardiovascular, hepatic, renal, endocrine, hematologic, neurological, psychiatric, or pulmonary diseases; uncontrolled hypertension; new onset diabetes (within 3 months), poorly controlled hyperglycemia, or hypoglycemia for any cause; evidence for metabolic bone disease other than osteoporosis; abnormal indices of calcium metabolism; and/or active renal stone disease~* User of illicit recreational drugs or has had a recent history (within the last year) of drug or alcohol abuse or dependence~* Heavy consumer of alcohol or alcohol containing products.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fosamax Plus (Type: EXPERIMENTAL): Calcium supplement (elemental calcium and/or calcium carbonate) without vitamin D will also be supplied to participants

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete